Identification of dihydrotanshinone I as an ERp57 inhibitor with anti-breast cancer properties via the UPR pathway.

MLA

Shi, Wei, et al. “Identification of Dihydrotanshinone I as an ERp57 Inhibitor with Anti-Breast Cancer Properties via the UPR Pathway.” Biochemical Pharmacology, vol. 190, Aug. 2021, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.bcp.2021.114637.

APA

Shi, W., Han, H., Zou, J., Zhang, Y., Li, H., Zhou, H., & Cui, G. (2021). Identification of dihydrotanshinone I as an ERp57 inhibitor with anti-breast cancer properties via the UPR pathway. Biochemical Pharmacology, 190, N.PAG. https://doi.org/10.1016/j.bcp.2021.114637

Chicago

Shi, Wei, Han Han, Jia Zou, Ying Zhang, Haitao Li, Hefeng Zhou, and Guozhen Cui. 2021. “Identification of Dihydrotanshinone I as an ERp57 Inhibitor with Anti-Breast Cancer Properties via the UPR Pathway.” Biochemical Pharmacology 190 (August): N.PAG. doi:10.1016/j.bcp.2021.114637.